glucose, (beta-d)-isomer has been researched along with Diabetic Nephropathies in 169 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.18) | 29.6817 |
| 2010's | 115 (68.05) | 24.3611 |
| 2020's | 52 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
| Guo, H; Jiao, X; Li, H; Li, X; Liu, J; Liu, Q; Qi, C; Wan, Z; Wang, R; Wang, Z; Wu, X; Zhang, H; Zhao, H | 1 |
| Wang, T; Wen, X; Xie, M; Zhang, Z; Zhou, J | 1 |
| Chen, G; Wang, H; Zhang, W; Zhou, J | 1 |
| Brand, SB; Kansal, AR; Koitka-Weber, A; Kuti, E; Pfarr, E; Reifsnider, OS; Stargardter, M; Ustyugova, A; Wang, C; Wanner, C | 1 |
| Alpers, CE; Holland, AL; Hudkins, KL; Li, X; Swaminathan, S | 1 |
| Benigni, A; Cerullo, D; Conti, S; Corna, D; Locatelli, M; Remuzzi, G; Rottoli, D; Tomasoni, S; Zanchi, C; Zoja, C | 1 |
| Khine, A; Kwok, J; Lin, E | 1 |
| Fan, X; Guo, F; Huang, F; Liu, Y; Qin, G; Song, Y; Zhao, L | 1 |
| Abegaz, TM; Ali, AA; Diaby, V; Sherbeny, F | 1 |
| Matsumoto, K; Tsuboi, N; Ueda, H; Yokoo, T | 1 |
| Huang, B; Wen, W; Ye, S | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Heerspink, HJL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Schechter, M; Wilding, JPH; Wiviott, SD; Yanuv, I; Zelniker, TA | 1 |
| Gao, L; Huang, YB; Jiang, L; Liu, XQ; Wang, AL; Wang, X; Wu, YG; Xia, LL; Zeng, HX; Zhu, QJ | 1 |
| Bao, Y; Pei, D; Piao, M; Tian, S; Xu, D; Zhang, J | 1 |
| Dai, Y; Fang, LJ; Hu, B; Lu, YP; Tang, C; Tang, DE; Wu, HW; Yin, L; Zhang, YQ; Zhang, ZY; Zheng, ZH; Zhu, T | 1 |
| Deng, L; Xu, G; Yang, Y | 1 |
| Bai, Z; Chen, L; Chen, Z; Liu, T; Luo, J; Xiao, Y; Xie, T; Yu, L; Zhang, C; Zhao, X | 1 |
| Aoki, K; Azushima, K; Hanaoka, M; Haruhara, K; Hosokawa, S; Inazumi, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, R; Kobayashi, Y; Kondo, Y; Misumi, T; Ohki, K; Ono, S; Orime, K; Osada, U; Sasaki, H; Shibasaki-Kurita, T; Tamura, K; Terauchi, Y; Wakui, H; Yamada, T; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Fagbote, C; Genovese, N; Hawley, CE; Li, J; Paik, JM; Triantafylidis, LK | 1 |
| Takakura, S; Takasu, T | 1 |
| Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH | 1 |
| Huang, L; Li, N; Liu, W; Miao, J; Wang, L; Yu, J | 1 |
| Beltrán-Romero, LM; León-Jiménez, D; Miramontes-González, JP; Moreno-Obregón, F | 1 |
| Baer, PC; Freitag, J; Geiger, H; Koch, B; Schubert, R | 1 |
| Foresto, RD; Gonzalez, DE; Ribeiro, AB | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; McMurray, J; Rossing, P; Stefansson, BV; Toto, R; Wheeler, DC | 1 |
| Shati, AA | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Shimatsu, A; Tanaka, M; Yamakage, H | 1 |
| Balogh, DB; Besztercei, B; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lenart, L; Sparding, N; Szabo, AJ; Wagner, LJ | 1 |
| Kanasaki, K; Kitada, M; Koya, D; Li, J; Liu, H; Nitta, K; Srivastava, SP; Takagaki, Y; Takagi, S | 1 |
| Amemiya, H; Asakura, T; Iemitsu, K; Ishikawa, M; Ito, S; Kanamori, A; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Matsuba, I; Matsuzawa, Y; Minagawa, F; Minami, N; Miyakawa, M; Mokubo, A; Shinoda, K; Takai, M; Takeda, H; Takihata, M; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y | 1 |
| Han, H; He, J; Hu, CY; Jiang, H; Li, XS; Qi, SS; Zheng, HX | 1 |
| Bgatova, NP; Dashkin, MV; Khotskina, AS; Klein, T; Klimontov, VV; Konenkov, VI; Korbut, AI; Muraleva, NA; Orlov, NB; Taskaeva, IS; Zavyalov, EL | 1 |
| Ferreira, JP; Fitchett, D; George, JT; Kraus, BJ; Lauer, S; Ofstad, AP; Rossignol, P; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Heerspink, HL; Helmlinger, G; Nieves, EH; Penland, RC; van Raalte, DH | 1 |
| Chen, L; Li, T; Li, X; Liu, X; Sun, B; Sun, H; Xu, C; Xu, L; Xue, M; Yu, X | 1 |
| Batiushin, M; Bilchenko, O; Cherney, DZI; Chertow, GM; Correa-Rotter, R; Douthat, W; Dwyer, JP; Escudero, E; Furuland, H; Górriz, JL; Greene, T; Haller, H; Heerspink, HJL; Hou, FF; Isidto, R; Kang, SW; Kashihara, N; Khullar, D; Langkilde, AM; Lindberg, M; Mark, PB; McMurray, JJV; Nowicki, M; Pecoits-Filho, R; Persson, F; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Umanath, K; Van Bui, P; Wheeler, DC; Wittmann, I | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; Mann, JFE; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Adachi, E; Gohda, T; Ichikawa, S; Koshida, T; Li, Z; Murakoshi, M; Suzuki, C; Suzuki, Y; Ueda, S | 1 |
| Papaetis, GS | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Azushima, K; Haruhara, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, Y; Kondo, Y; Misumi, T; Osada, U; Tamura, K; Terauchi, Y; Wakui, H; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Fukuda, S; Ishii, Y; Kemmochi, Y; Kuroki, F; Miyajima, K; Nakae, D; Ohta, T; Sano, R; Sasase, T; Sugimoto, M; Yamanaka, M; Yasui, Y | 1 |
| El Fayoumi, HM; Elkazzaz, SK; Khodeer, DM; Moustafa, YM | 1 |
| Larmour, K; Levin, A | 1 |
| Li, S; Si, Z; Wang, D; Xue, Y; Yang, Y; Zhang, Z | 1 |
| Abdel-Kareem, MA; Ahmed, AS; Elsisy, RA; Mona, MM | 1 |
| Baines, DL; Dockrell, MEC; Pan, X; Phanish, MK | 1 |
| Berrut, G; Boureau, AS; de Decker, L; Genet, B; Hanon, O; Trochu, JN | 1 |
| Birnbaum, Y; Chen, H; Nylander, S; Tran, D; Ye, Y | 1 |
| Dai, X; Duan, JA; Qian, D; Shang, EX; Su, S; Wang, Q; Wei, D; Xiang, X; Xu, Z; Zheng, T | 1 |
| Mori, K; Nakamura, S; Ogawa, Y; Okuma, H; Sekine, T; Tsuchiya, K | 1 |
| Bu, W; Chen, J; Ding, W; Feng, L; Hou, X; Jia, X; Ma, S; Sun, S; Zhang, M; Zhao, D; Zhu, M | 1 |
| Hongchao, X; Jiangang, L; Ni, Z; Qiujing, W; Tao, L; Weikang, H; Xiaohui, X; Xin, L; Zelin, Z; Zhao, S | 1 |
| Krzesinski, JM; Paquot, N; Piérard, L; Scheen, AJ | 1 |
| Palau, V; Riera, M; Soler, MJ | 1 |
| Wanner, C | 3 |
| Cai, HD; Dai, XX; Duan, JA; Guo, S; Qian, DW; Shang, EX; Su, SL; Wei, DD; Yan, H; Zheng, TY; Zhu, ZH | 1 |
| Chilton, RJ | 1 |
| Shao, Y; Wang, K; Wu, Y; Zhang, T; Zhu, Q | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Toto, RD | 1 |
| Athyros, VG; Doumas, M; Imprialos, KP; Karagiannis, A; Stavropoulos, K | 1 |
| Broedl, UC; Cherney, DZI; Cooper, ME; Johansen, OE; Lund, SS; Pfarr, E; Tikkanen, I; Woerle, HJ | 1 |
| Ohno, Y; Suzuki, H; Takenaka, T | 1 |
| Qi, XM; Shao, YX; Wang, K; Wu, YG; Xu, XX | 1 |
| Chang, B; Chen, W; Fan, R; Guo, Y; Liu, L; Pan, Y; Zhao, R | 1 |
| Tahara, A; Takasu, T | 2 |
| Bajaj, M; Birnbaum, Y; Yang, HC; Ye, Y | 1 |
| Cherney, DZ; Dekkers, CCJ; Gansevoort, RT; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Anzai, T; Asakura, M; Hamasaki, T; Hashimura, K; Imazu, M; Ito, S; Kitakaze, M; Mori, K; Watanabe, M; Yamamoto, H; Yasuda, S; Yasumura, Y; Yoshihara, F | 1 |
| Abdel-Wahab, AF; Al-Harizy, RM; Bamagous, GA; ElSawy, NA; Ghamdi, SSA; Ibrahim, IA; Shahzad, N | 1 |
| Li, X; Wang, K; Wang, Y; Wu, Y | 1 |
| Gao, Q; Yang, M; Zuo, Z | 1 |
| Cherney, DZI; Heerspink, HJL; Inzucchi, SE; Kosiborod, M | 1 |
| Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Pfarr, E; Verma, S; Zinman, B | 1 |
| Cao, M; Li, Y; Qin, Y; Wang, T; Xu, Y; Zhai, Q; Zhao, K | 1 |
| de Albuquerque Rocha, N; McCullough, PA; McGuire, DK; Neeland, IJ; Toto, RD | 1 |
| Aroor, AR; Carpenter, AJ; Chandrasekar, B; Das, NA; DeMarco, VG; Duta, C; Habibi, J; Hayden, MR; Jia, G; Manrique-Acevedo, CM; Martinez-Lemus, L; Mayoux, E; Nistala, R; Padilla, J; Ramirez-Perez, FI | 1 |
| Iida, S; Ikeda, S; Kasahara-Ito, N; Portron, A; Saito, T; Schwab, D; Takano, Y | 1 |
| Cherney, DZI; Thomas, MC | 1 |
| Anichini, R; Avogaro, A; Del Prato, S; Fadini, GP; Gatti, A; Manca, ML; Penno, G; Solini, A | 1 |
| Hantel, S; Kadowaki, T; Koitka-Weber, A; Nangaku, M; Okamura, T; von Eynatten, M; Wanner, C | 1 |
| Cain, VA; Hallow, MK; Heerspink, HJL; Inzucchi, SE; Rossing, P; Sartipy, P; Sjöström, CD; Stefansson, BV | 1 |
| Assaf, N; El-Yamany, MF; Ghoneim, HA; Oraby, MA; Safar, MM | 1 |
| Arvapalli, R; Bandarupalli, VVK; Blough, ER; Ginjupalli, GK; Graffeo, VA; Manne, NDPK; Rice, KM | 1 |
| Huang, X; Li, P; Liu, Y; Luo, Y; Qin, X; Sun, C; Wu, C; Xue, H | 1 |
| Mallamaci, F; Zoccali, C | 1 |
| Heerspink, HJL; Idzerda, NMA; Pena, MJ; Sjostrom, DC; Stefansson, BV; Wheeler, DC | 1 |
| Chen, M; Leng, W; Liu, C; Shang, C | 1 |
| Cherney, DZI; Hantel, S; Inzucchi, SE; Koitka-Weber, A; Mayer, GJ; von Eynatten, M; Wanner, C; Weir, MR; Zinman, B | 1 |
| Cooper, ME; Hantel, S; Inzucchi, SE; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zinman, B | 1 |
| Bastie, CC; Kaira, K; Maeshima, A; Nakajima, Y; Okada, S; Shibusawa, R; Yamada, E; Yamada, M | 1 |
| Briand, F; Galsgaard, ED; Nørgaard, SA; Sand, FW; Sulpice, T; Søndergaard, H; Sørensen, DB | 1 |
| Cui, TX; Fang, XL; He, QL; Ibrahim Rage, H; Li, YJ; Lv, WZ; Xie, RY; Zheng, XB; Zhu, WP | 1 |
| Cobble, ME; Kluger, AY; Lee, AY; Lepor, NE; Lerma, EV; McCullough, PA; Rangaswami, J; Tecson, KM | 1 |
| Fukazawa, M; Fukuzawa, T; Honda, K; Kawabe, Y; Mori, T; Nagata, T; Nihei, T; Suzuki, Y; Takeda, M | 1 |
| Cai, X; Cao, P; Gu, Z; Guan, X; Hu, C; Lu, W; Qian, S; Wang, D; Yang, J; Yao, Y; Zhou, F | 1 |
| Broedl, UC; Halabi, A; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ | 1 |
| Broedl, UC; Cinca, R; Macha, S; Mattheus, M; Pinnetti, S; Rose, P; Woerle, HJ | 1 |
| Feng, L; Gu, JF; Jia, XB; Wu, C; Zhang, MH; Zhu, MM | 1 |
| Fioretto, P; Kohan, DE; List, JF; Tang, W | 2 |
| Kirk, R | 1 |
| Gerasimova, M; Koepsell, H; Masuda, T; Mayoux, E; Rieg, T; Rose, MA; Satriano, J; Thomson, SC; Vallon, V | 1 |
| Gilbert, RE | 2 |
| Liu, DL; Ma, ST | 1 |
| Scheen, AJ | 1 |
| Qi, XM; Shen, JJ; Wang, K; Wu, XX; Wu, YG; Xu, XX; Zhang, CQ; Zhang, W | 1 |
| Seufert, J | 1 |
| Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Tokudome, T; Ueda, N; Yang, J | 1 |
| Bartaun, C; Gembardt, F; Hohenstein, B; Hugo, C; Jarzebska, N; Mayoux, E; Todorov, VT | 1 |
| Eguchi, J; Hatanaka, T; Horiguchi, CS; Makino, H; Nakatsuka, A; Nishii, N; Ogawa, D; Tachibana, H; Takei, K; Terami, N; Wada, J; Yamada, H | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D | 1 |
| Bakris, G; Davies, M; de Zeeuw, D; Kline, I; Mayer, C; Meininger, G; Perkovic, V; Usiskin, K; Vijapurkar, U; Woo, V; Yamout, H | 1 |
| Li, H; Ren, X; Yu, W; Zhang, W; Zhao, C | 1 |
| Chen, C; Hao, J; Huang, H; Huang, J; Huang, K; Liu, P; Wang, S | 1 |
| Sherif, IO | 1 |
| Gangadharan Komala, M; Gross, S; Huang, C; Mather, A; Mudaliar, H; Panchapakesan, U; Pegg, K; Pollock, CA; Shen, S | 1 |
| Navarro, D | 1 |
| Robson, AF; Shipman, KE | 1 |
| Cherney, DZ; Škrtić, M | 1 |
| Matsui, T; Nakamura, N; Nishino, Y; Ojima, A; Yamagishi, S | 1 |
| Chang, BC; Chen, WD; Liu, L; Wang, J; Yang, P; Zhang, Y | 1 |
| Bakris, GL; Majewski, C | 1 |
| Du, C; Duan, H; Hou, Y; Ren, Y; Shi, Y; Wei, J; Wu, H; Wu, M; Yao, F | 1 |
| Gao, G; Wang, Y; Yang, X | 1 |
| Bai, X; Bian, F; Chi, J; Jin, S; Li, W; Wang, J; Wu, D; Wu, G; Xing, S; Xu, G; Yang, X; Zheng, T | 1 |
| Weir, MR | 1 |
| Hayashizaki, Y; Takakura, S; Takasu, T; Toyoshi, T | 1 |
| Borg, DJ; Flemming, NB; Forbes, JM; Fotheringham, AK; Gallo, LA; Harvie, BM; Kinneally, TL; Koepsell, H; McCarthy, DA; Panchapakesan, U; Pollock, C; Vallon, V; Ward, MS; Yeh, SM; Zhuang, A | 1 |
| Broedl, UC; Fitchett, D; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; von Eynatten, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Cain, VA; Fioretto, P; Johnsson, E; Sjöström, CD; Stefansson, BV | 1 |
| Ingelfinger, JR; Rosen, CJ | 1 |
| Qi, X; Wang, K; Wu, Y; Zhu, Q | 1 |
| Chang, YK; Choi, DE; Choi, H; Jeong, JY; Lee, KW; Lim, BJ; Na, KR | 1 |
| Ishibashi, Y; Matsui, T; Yamagishi, SI | 1 |
| Harada, M; Kawamura, T; Miyazaki, Y; Nakayama, I; Ogura, M; Okonogi, H; Sato, H; Tokoro, K; Tsuboi, N; Yokoo, T | 1 |
| Busetto, L; Fioretto, P; Rossato, M; Vettor, R; Zambon, A | 1 |
| Chen, BB; Chen, GT; Song, Y; Yang, M; Zhang, W; Zhang, Y | 1 |
| Ahn, YB; Chung, S; Kim, ES; Kim, JW; Kim, MJ; Kim, SJ; Ko, SH; Lee, EM; Moon, SD; Shin, SJ; Yoo, YH | 1 |
| Anders, HJ; Davis, JM; Thurau, K | 1 |
| Mende, CW | 1 |
| Breyer, MD; Susztak, K | 1 |
| Koya, D | 1 |
| Kazazis, C; Trigkidis, K; Vallianou, NG | 1 |
| Li, D; Li, Y; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH | 1 |
| Avogaro, A; Fioretto, P | 1 |
| Cai, W; Chen, Q; Chen, Z; Gong, W; Huang, H; Huang, J; Li, J; Liu, P | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, SI | 1 |
| Qi, XM; Shen, JJ; Su, J; Wu, YG; Zhang, JJ; Zhang, P | 1 |
| Han, HK; Jung, ME; Kang, J; Kim, J; Lee, J; Lee, M; Lee, SH; Seo, HJ; Son, EJ | 1 |
| Goyal, RK; Lakshmi, S; Padh, H; Rajani, M; Sonawane, RD; Vishwakarma, SL | 1 |
| Sharma, K; Vallon, V | 1 |
| Cai, F; Jia, Y; Li, C; Li, J; Liu, Q; Tang, J; Wang, C; Yang, Y; Zhao, X | 1 |
| Huang, H; Huang, J; Huang, K; Liu, P; Peng, J; Shen, X; Xie, X | 1 |
| Qi, XM; Su, J; Wang, K; Wu, YG; Zhang, JJ; Zhang, P | 1 |
| Komala, MG; Mather, A; Panchapakesan, U; Pollock, C | 1 |
| Deng, JJ; Liu, DL; Liu, RB; Ma, ST; Niu, R | 1 |
| Forbes, J; Gross, S; Komala, MG; Mather, A; Mudaliar, H; Panchapakesan, U; Pegg, K; Pollock, C | 1 |
| Chen, YP; Wang, HY | 1 |
| Arakawa, K; Ishihara, T; Kitamura, K; Matsumoto, M; Nawano, M; Oku, A; Saito, A; Ueta, K | 1 |
26 review(s) available for glucose, (beta-d)-isomer and Diabetic Nephropathies
| Article | Year |
|---|---|
SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Diseases; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Treatment Outcome | 2016 |
SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke | 2017 |
Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arctium; Cell Line, Tumor; Diabetic Nephropathies; Furans; Glucosides; Humans; Lignans; Neuroprotective Agents; Pancreatic Neoplasms | 2018 |
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Hospitalization; Humans; Kidney; Protective Agents; Renal Elimination; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Topics: Adiposity; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Nonproteinuric progressive diabetic kidney disease.
Topics: Albuminuria; Benzhydryl Compounds; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Proteomics; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Kidney; Protective Factors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
[Progress of pharmacological actions of total glucosides of paeony in treating diabetic nephropathy].
Topics: Diabetic Nephropathies; Glucosides; Humans; Paeonia; Phytotherapy | 2013 |
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Glucosides; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Kidney Concentrating Ability; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Thiophenes | 2015 |
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
.
Topics: Angiotensins; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Protective Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction | 2017 |
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Renal Insufficiency; Reproducibility of Results; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2017 |
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Topics: Absorption; Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Sodium glucose cotransporter 2 and the diabetic kidney.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
26 trial(s) available for glucose, (beta-d)-isomer and Diabetic Nephropathies
| Article | Year |
|---|---|
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Renal Plasma Flow; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Medicare; Myocardial Infarction; United States | 2022 |
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Myocardial Infarction; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes st
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Japan; Kidney; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2019 |
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Gliclazide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Vasoconstriction; Vasodilation | 2020 |
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2020 |
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Uric Acid; Young Adult | 2020 |
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Prognosis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Regression Analysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Topics: Acute Kidney Injury; Adult; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hepatitis A Virus Cellular Receptor 1; Humans; Inflammation Mediators; Interleukin-6; Kidney Glomerulus; Kidney Tubules; Netherlands; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Humans; Japan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Coronary Artery Bypass; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Risk; Treatment Outcome | 2018 |
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Elimination; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Topics: Albuminuria; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Analysis from the EMPA-REG OUTCOME
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Male; Middle Aged; Protective Agents; Regional Blood Flow; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Topics: Adult; Aged; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Administration Schedule; Fasting; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
Topics: Adult; Aged; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fasting; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Topics: Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Fasting; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney; Male; Microvessels; Middle Aged; Proportional Hazards Models; Risk Factors | 2016 |
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glucosides; Humans; Losartan; Male; Middle Aged; Paeonia; Phytotherapy; Plant Extracts; Plant Roots; Prospective Studies; Serum Albumin; Tumor Necrosis Factor-alpha | 2016 |
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
Topics: Adolescent; Adult; Aged; Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Placebos; Reproducibility of Results; Treatment Outcome; Young Adult | 2017 |
[Clinical observation on treatment of diabetic nephropathy with compound fructus arctii mixture].
Topics: Adult; Albuminuria; Astragalus propinquus; Diabetic Nephropathies; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Furans; Glucosides; Humans; Losartan; Male; Middle Aged; Phytotherapy | 2004 |
117 other study(ies) available for glucose, (beta-d)-isomer and Diabetic Nephropathies
| Article | Year |
|---|---|
The combination of ursolic acid and empagliflozin relieves diabetic nephropathy by reducing inflammation, oxidative stress and renal fibrosis.
Topics: Animals; Anti-Inflammatory Agents; Antifibrotic Agents; Antioxidants; Apoptosis; Benzhydryl Compounds; Cell Line; Cell Proliferation; Diabetic Nephropathies; Drug Therapy, Combination; Fibrosis; Glucosides; Inflammation Mediators; Kidney; Male; Nephritis; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Triterpenes; Ursolic Acid | 2021 |
Phillyrin ameliorates diabetic nephropathy through the PI3K/Akt/GSK-3β signalling pathway in streptozotocin-induced diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Glucosides; Glycogen Synthase Kinase 3 beta; Kidney; Male; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Random Allocation | 2021 |
Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cell Line; Cyclic AMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Epithelial Cells; Female; Follow-Up Studies; Glucosides; Humans; Male; MAP Kinase Signaling System; Middle Aged; Renal Elimination; Retrospective Studies; RNA-Seq; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2021 |
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Mice; Mice, Inbred Strains; Proteinuria; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Caveolin 1; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelial Cells; Female; Glomerular Basement Membrane; Glucosides; Humans; Male; Mice; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Endothelial Growth Factor A | 2022 |
Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents | 2022 |
Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Glucose; Glucosides; Humans; Hypoglycemic Agents; In Situ Hybridization, Fluorescence; Metformin; MicroRNAs; RNA, Circular; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2022 |
Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus; Diabetic Nephropathies; Drug-Related Side Effects and Adverse Reactions; Glucosides; Humans; Medicare; Quality-Adjusted Life Years; Standard of Care; United States | 2022 |
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Dapagliflozin Ameliorates Renal Tubular Ferroptosis in Diabetes via SLC40A1 Stabilization.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Ferroptosis; Glucosides; Mice; Mice, Inbred C57BL | 2022 |
Paeoniflorin binds to VEGFR2 to restore autophagy and inhibit apoptosis for podocyte protection in diabetic kidney disease through PI3K-AKT signaling pathway.
Topics: Animals; Apoptosis; Autophagy; Caspase 3; Class I Phosphatidylinositol 3-Kinases; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Mice; Molecular Docking Simulation; Monoterpenes; Phosphatidylinositol 3-Kinases; Podocytes; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Protective effect of salidroside on streptozotocin-induced diabetic nephropathy by inhibiting oxidative stress and inflammation in rats via the Akt/GSK-3β signalling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucosides; Glycogen Synthase Kinase 3 beta; Inflammation; Male; Oxidative Stress; Phenols; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Streptozocin | 2022 |
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease.
Topics: Animals; Benzhydryl Compounds; Chromatography, Liquid; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Kidney; Mice; Proteomics; Sodium-Glucose Transporter 2 Inhibitors; Tandem Mass Spectrometry | 2022 |
Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota.
Topics: Albumins; Animals; Anti-Bacterial Agents; Bacteria; Benzhydryl Compounds; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Volatile; Gastrointestinal Microbiome; Glucosides; Lipopolysaccharides; Mice; Occludin; RNA, Ribosomal, 16S; Sodium; Sodium-Glucose Transporter 2; Streptozocin | 2022 |
An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy.
Topics: Albumins; Animals; Benzhydryl Compounds; Caspase 3; Chemokines; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Interleukin-10; Mice; Network Pharmacology; PPAR gamma; RNA, Long Noncoding; RNA, Messenger; Sequence Analysis, RNA; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta | 2022 |
A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Nephrology; Pharmacists; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Topics: Animals; Blood Glucose; Blood Pressure; Chlorides; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Heart Rate; Male; Rats, Sprague-Dawley; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ameliorative effect of polydatin on hyperglycemia and renal injury in streptozotocin-induced diabetic rats.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose Transporter Type 1; Glucose Transporter Type 4; Glucosides; HEK293 Cells; Humans; Hyperglycemia; Inflammation; Mice; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Stilbenes | 2019 |
Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Glucosides; Hemodynamics; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
Topics: Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Epithelial Cells; Gene Expression Regulation; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Kidney; Kidney Tubules, Proximal; Oxidative Stress; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Salidroside ameliorates diabetic nephropathy in rats by activating renal AMPK/SIRT1 signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Kidney; Phenols; Rats; Signal Transduction; Sirtuin 1 | 2020 |
Reduced
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cell Hypoxia; Cell Line; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fibronectins; Fibrosis; Glucosides; Glycosylation; Humans; Kidney Tubules, Proximal; Male; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2020 |
Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Glucosides; Glycolysis; Kidney Tubules, Proximal; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Cyanidin-3-glucoside from Black Rice Ameliorates Diabetic Nephropathy via Reducing Blood Glucose, Suppressing Oxidative Stress and Inflammation, and Regulating Transforming Growth Factor β1/Smad Expression.
Topics: Animals; Anthocyanins; Blood Glucose; Diabetic Nephropathies; Glucosides; Humans; Male; Oryza; Oxidative Stress; Plant Extracts; Rats; Rats, Sprague-Dawley; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1 | 2020 |
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Topics: Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Biomarkers; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Glucosides; Immunohistochemistry; Kidney Function Tests; Kidney Glomerulus; Linagliptin; Mice; Mice, Inbred Strains; Mice, Transgenic; Podocytes; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Mortality; Sodium-Glucose Transporter 2 Inhibitors; Treatment Failure; Treatment Outcome | 2020 |
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
Topics: Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Models, Biological; Randomized Controlled Trials as Topic; Renal Insufficiency; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Cell Line; Diabetic Nephropathies; Glucosides; Humans; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Mitochondrial Dynamics; Phosphorylation; Signal Transduction; Sodium-Glucose Transporter 2; Sp1 Transcription Factor | 2020 |
The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Male; Mice; Mice, Obese; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Sodium, Dietary | 2021 |
Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerular Filtration Rate; Glucosides; Hyperglycemia; Male; Obesity; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Glucosides; Inflammation; Kidney; Male; Rats; Sodium-Glucose Transporter 2 Inhibitors; Vascular Endothelial Growth Factor A | 2021 |
Slowing Progression in CKD: DAPA CKD and Beyond.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Glucosides; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease.
Topics: Animals; Benzhydryl Compounds; China; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Immediate-Early Proteins; Male; Mice; Mice, Inbred C57BL; Protein Serine-Threonine Kinases; T-Lymphocytes, Regulatory; Th17 Cells | 2021 |
SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction.
Topics: Acute Kidney Injury; Animals; Benzhydryl Compounds; Cell Adhesion Molecules; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Electrocardiography; Glucosides; Kidney; Lipocalin-2; Male; Myocardial Infarction; Oxidative Stress; Rats; Rats, Wistar; RNA, Messenger; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model.
Topics: Benzhydryl Compounds; Cells, Cultured; Connective Tissue Growth Factor; Diabetic Nephropathies; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Glucose; Glucosides; Humans; Kidney Tubules, Proximal; Phosphorylation; Signal Transduction; Smad2 Protein; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1 | 2021 |
[Empagliflozin in the elderly].
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus.
Topics: Albumins; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Benzhydryl Compounds; Creatinine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eosine Yellowish-(YS); Glucose; Glucosides; Hematoxylin; Inflammasomes; Insulins; Kidney; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Periodic Acid; Proto-Oncogene Proteins c-akt; Ticagrelor | 2022 |
A natural product of acteoside ameliorate kidney injury in diabetes db/db mice and HK-2 cells via regulating NADPH/oxidase-TGF-β/Smad signaling pathway.
Topics: Animals; Biological Products; Cell Line; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Humans; Kidney; Male; Mice; NADP; NADPH Oxidases; Phenols; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2021 |
Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucosides; Kidney Glomerulus; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Paeoniflorin ameliorates AGEs-induced mesangial cell injury through inhibiting RAGE/mTOR/autophagy pathway.
Topics: Animals; Autophagosomes; Autophagy; Cell Line; Diabetic Nephropathies; Glucosides; Glycation End Products, Advanced; Mesangial Cells; Microtubule-Associated Proteins; Monoterpenes; Rats; Receptor for Advanced Glycation End Products; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
Polydatin impairs mitochondria fitness and ameliorates podocyte injury by suppressing Drp1 expression.
Topics: Animals; Apoptosis; Blood Glucose; Cell Line; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Dynamins; Glucosides; Mice, Inbred C57BL; Mitochondria; Mitochondrial Dynamics; Podocytes; Reactive Oxygen Species; RNA Interference; Signal Transduction; Stilbenes; Transfection | 2017 |
The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?
Topics: Albuminuria; Anti-Inflammatory Agents; Benzhydryl Compounds; Cardiovascular Diseases; Cytokines; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Heart; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Oxidative Stress; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Comparative pharmacokinetics of acteoside from total glycoside extracted from leaves of Rehmannia and Dihuangye total glycoside capsule in normal and diabetic nephropathy rats.
Topics: Animals; Chromatography, High Pressure Liquid; Diabetic Nephropathies; Drug Stability; Glucosides; Glycosides; Male; Mass Spectrometry; Phenols; Plant Extracts; Plant Leaves; Rats; Rats, Sprague-Dawley; Rehmannia; Reproducibility of Results | 2017 |
Introduction.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Sodium-Glucose Transporter 2 Inhibitors; Stroke | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Paeoniflorin prevents TLR2/4-mediated inflammation in type 2 diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; China; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Medicine, Chinese Traditional; Mice; Monoterpenes; Protective Agents; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2017 |
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Resistance; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency; Renin-Angiotensin System; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2018 |
Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 | 2018 |
Paeoniflorin attenuates incipient diabetic nephropathy in streptozotocin-induced mice by the suppression of the Toll-like receptor-2 signaling pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Dose-Response Relationship, Drug; Glucosides; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Conformation; Monoterpenes; Signal Transduction; Streptozocin; Structure-Activity Relationship; Toll-Like Receptor 2 | 2017 |
[Triperygium wilfordii multiglucoside ameliorates kidney damage in diabetic rats by inhibiting the expressions of MBL and MASP2].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression; Glucosides; Male; Mannose-Binding Lectin; Mannose-Binding Protein-Associated Serine Proteases; Phytotherapy; Plant Preparations; Rats, Sprague-Dawley; Tripterygium | 2017 |
Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Topics: Adamantane; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammasomes; Inflammation Mediators; Kidney; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammation Mediators; Irbesartan; Kidney; Male; Organ Size; Oxidative Stress; Protective Agents; Rats, Wistar; Tetrazoles | 2018 |
Renal protective effect of Paeoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Glucosides; Humans; Janus Kinase 2; Kidney; Macrophages; Male; Mice; Mice, Inbred C57BL; Monoterpenes; Signal Transduction; STAT3 Transcription Factor; Streptozocin | 2018 |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Hypertension; Kidney; Losartan; Male; Mice, Inbred C57BL; Nephrectomy; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Cyanidin-3-O-glucoside ameliorates diabetic nephropathy through regulation of glutathione pool.
Topics: Animals; Anthocyanins; Buthionine Sulfoximine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Glucose; Glucosides; Glutathione; Inflammation; Kidney; Lipid Metabolism; Male; Mice, Inbred C57BL; Obesity; Protective Agents | 2018 |
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Endothelium, Vascular; Female; Glucosides; Glycosuria; GPI-Linked Proteins; Humans; Kidney; Mice, Inbred C57BL; Mice, Mutant Strains; Pulsatile Flow; Renal Circulation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Vascular Stiffness; Vasodilation | 2018 |
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Italy; Kidney; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Treatment Outcome | 2019 |
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Topics: Aged; Albumins; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors | 2019 |
Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fructose; Glucosides; Male; Pilot Projects; Random Allocation; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2019 |
Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Administration Schedule; Glucosides; Kidney; Maintenance Chemotherapy; Male; Obesity; Rats; Rats, Zucker; Time Factors | 2020 |
Salidroside stimulates the Sirt1/PGC-1α axis and ameliorates diabetic nephropathy in mice.
Topics: Animals; Diabetic Nephropathies; Disease Models, Animal; DNA, Mitochondrial; Electron Transport; Glucosides; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondria; Phenols; Podocytes; Sirtuin 1; Streptozocin; Transcription Factors; Up-Regulation | 2019 |
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
[Effects and mechanism of salidroside on streptozotocin-induced mode rats of diabetic nephropathy].
Topics: Animals; Diabetic Nephropathies; Glucosides; Kidney; Phenols; Rats; Rats, Sprague-Dawley; Signal Transduction; Streptozocin; Transforming Growth Factor beta1 | 2019 |
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Global Health; Glucosides; Humans; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Cell Death; Cell Line; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Epithelial Cells; Glucose; Glucosides; Humans; Kidney; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetic Nephropathies; Diet, High-Protein; Disease Progression; Gene Expression Regulation; Glucosides; Kidney; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2019 |
Salidroside and FG-4592 ameliorate high glucose-induced glomerular endothelial cells injury via HIF upregulation.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Survival; Cells, Cultured; Diabetic Nephropathies; Endothelial Cells; Glucose; Glucosides; Glycine; Hypoxia-Inducible Factor 1, alpha Subunit; Isoquinolines; Kidney Glomerulus; Phenols; Protein Stability; Rats; Up-Regulation | 2019 |
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Female; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Kidney; Losartan; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2013 |
The aqueous extract of Lycopus lucidus Turcz ameliorates streptozotocin-induced diabetic renal damage via inhibiting TGF-β1 signaling pathway.
Topics: Animals; Caffeic Acids; Cell Line; Cinnamates; Depsides; Diabetic Nephropathies; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Glucosides; Humans; Luteolin; Lycopus; Male; Mice; Phosphorylation; Plant Extracts; Plants, Medicinal; Rats; Rats, Sprague-Dawley; Rosmarinic Acid; Signal Transduction; Streptozocin; Transforming Growth Factor beta1 | 2013 |
Antioxidative and anti-inflammatory activities of paeoniflorin and oxypaeoniflora on AGEs-induced mesangial cell damage.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzoates; Bridged-Ring Compounds; Catalase; Chemokine CCL2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glucosides; Glutathione Peroxidase; Glycation End Products, Advanced; Inflammation; Inhibitory Concentration 50; Interleukin-6; Macrophages; Mesangial Cells; Monoterpenes; Oxidative Stress; Paeonia; Phytotherapy; Rats | 2013 |
Diabetes: efficacy of dapagliflozin associated with renal function.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2013 |
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Topics: Adipocytes; Albuminuria; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Blotting, Western; Diabetes Mellitus; Diabetic Nephropathies; Drinking; Eating; Glomerular Filtration Rate; Glucosides; Heart Rate; Hyperglycemia; Inflammation; Kidney; Kidney Glomerulus; Mice; Mice, Inbred Strains; Real-Time Polymerase Chain Reaction; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Effects of total glucosides of paeony on immune regulatory toll-like receptors TLR2 and 4 in the kidney from diabetic rats.
Topics: Albumins; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucosides; Kidney; Macrophages; Male; Myeloid Differentiation Factor 88; Paeonia; Phytotherapy; Plant Extracts; Rats, Wistar; RNA, Messenger; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2014 |
The perils of clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2014 |
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Female; Glucosides; Hypertension; Hypertrophy; Hypoglycemic Agents; Kidney; Mice; Mice, Obese; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Blood Glucose; Body Weight; Cells, Cultured; Diabetic Nephropathies; Disease Models, Animal; Gene Expression; Glomerular Mesangium; Glucose; Glucosides; Homeostasis; Inflammation; Insulin-Secreting Cells; Kidney; Kidney Cortex; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2014 |
[Effects of tripterygium wilfordii polyglucoside on expression of Activin A and influence of transdifferentiation in renal tubulointerstitium of rats with diabetic nephropathy].
Topics: Activins; Animals; Cell Transdifferentiation; Diabetic Nephropathies; Glucosides; Kidney Tubules; Male; Rats; Rats, Wistar; Tripterygium | 2014 |
Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Gene Silencing; Glucosides; Glycation End Products, Advanced; Mesangial Cells; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Response Elements; Sirtuin 1; Stilbenes; Transforming Growth Factor beta1; Up-Regulation | 2015 |
Secoisolariciresinol diglucoside in high-fat diet and streptozotocin-induced diabetic nephropathy in rats: a possible renoprotective effect.
Topics: Animals; Apoptosis; Butylene Glycols; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet, High-Fat; Drug Evaluation, Preclinical; Glucosides; Hypoglycemic Agents; Kidney; Male; Microtubule-Associated Proteins; Nitric Oxide Synthase Type II; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; Streptozocin; Survivin; Tumor Necrosis Factor-alpha | 2014 |
Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Benzimidazoles; Benzoates; Blood Glucose; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Glucose Transporter Type 1; Glucosides; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Telmisartan; Toll-Like Receptor 2; Transforming Growth Factor beta1 | 2014 |
A report from the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) (September 15-19, 2014 - Vienna, Austria).
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Humans; Linagliptin | 2014 |
Dapagliflozin does not show improvement in glycemic control in moderate renal impairment: a question of analytical rigor?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2014 |
The authors reply.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2014 |
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibromyalgia; Gene Expression; Glucosides; Glycation End Products, Advanced; Hypoglycemic Agents; Inflammation; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
[Effect of total glucosides of paeony on Wnt/β-catenin signal transduction pathway expression in kidney of diabetic rats].
Topics: Animals; beta Catenin; Blood Glucose; Blood Urea Nitrogen; Diabetic Nephropathies; Drugs, Chinese Herbal; Glucosides; Humans; Kidney; Male; Paeonia; Rats; Rats, Sprague-Dawley; Wnt Signaling Pathway; Wnt1 Protein | 2014 |
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Anthocyanins inhibit high-glucose-induced cholesterol accumulation and inflammation by activating LXRα pathway in HK-2 cells.
Topics: Anthocyanins; Anti-Inflammatory Agents; ATP Binding Cassette Transporter 1; Cell Line; Cholesterol; Diabetic Nephropathies; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucose; Glucosides; Humans; Inflammation Mediators; Kidney; Liver X Receptors; Nephritis; Orphan Nuclear Receptors; PPAR alpha; RNA Interference; Signal Transduction; Time Factors; Transfection | 2015 |
High glucose induces rat mesangial cells proliferation and MCP-1 expression via ROS-mediated activation of NF-κB pathway, which is inhibited by eleutheroside E.
Topics: Animals; Cell Proliferation; Chemokine CCL2; Diabetic Nephropathies; Disease Models, Animal; Gene Expression Regulation; Glucose; Glucosides; Humans; I-kappa B Proteins; Lignans; Mesangial Cells; NADPH Oxidases; NF-kappa B; NF-KappaB Inhibitor alpha; Rats; Reactive Oxygen Species; Signal Transduction; Transcription Factor RelA | 2016 |
A novel mechanism of action for salidroside to alleviate diabetic albuminuria: effects on albumin transcytosis across glomerular endothelial cells.
Topics: Albumins; Albuminuria; AMP-Activated Protein Kinases; Animals; Caveolin 1; Creatinine; Diabetic Nephropathies; Endothelial Cells; Glucose; Glucosides; In Vitro Techniques; Kidney Glomerulus; Mesangial Cells; Mice; Phenols; Phosphorylation; src-Family Kinases; Transcytosis | 2016 |
Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Glucosides; Hyperglycemia; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Administration Schedule; Glucosides; Hepatitis A Virus Cellular Receptor 1; Hypoglycemic Agents; Lipocalin-2; Male; Mice; Treatment Outcome | 2016 |
Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male | 2016 |
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; bcl-2-Associated X Protein; Benzhydryl Compounds; Cell Hypoxia; Cell Line; Diabetic Nephropathies; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Glucosides; Hypoxia-Inducible Factor 1; Kidney Diseases; Kidney Tubules, Proximal; Male; Mice; Reperfusion Injury; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 inhibitors and renal function.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred C57BL; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury.
Topics: Brain Injuries, Traumatic; Diabetes Mellitus; Diabetic Nephropathies; Fludrocortisone; Glucosides; Humans; Hyponatremia; Insulin; Male; Middle Aged; Sodium; Thiophenes | 2016 |
SGLT2 Inhibitors and the Diabetic Kidney.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Renin-Angiotensin System; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside exerted protective effects on diabetic nephropathy in mice with hyperglycemia induced by streptozotocin.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Glucosides; Kidney; Male; Mice; Mice, Inbred C57BL; RNA, Messenger; Stilbenes | 2016 |
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Topics: Aldosterone; Animals; Benzhydryl Compounds; Chymosin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Hyperglycemia; Kidney; Lipid Peroxidation; Male; Rats, Inbred OLETF; Renin-Angiotensin System; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Nephron Protection in Diabetic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Nephrons; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Impact of empagliflozin on diabetic kidney disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating CKIP-1 to resist HG-induced up-regulation of FN and ICAM-1 in GMCs and diabetic mice kidneys.
Topics: Animals; Antioxidants; Carboxylic Ester Hydrolases; Carrier Proteins; Diabetic Nephropathies; Fibronectins; Gene Expression Regulation; Glucose; Glucosides; Humans; Hydrogen Peroxide; Intercellular Adhesion Molecule-1; Kelch-Like ECH-Associated Protein 1; Mesangial Cells; Mice; Mice, Inbred NOD; NF-E2-Related Factor 2; Signal Transduction; Stilbenes; Superoxides | 2017 |
Effects of total glucosides of paeony on oxidative stress in the kidney from diabetic rats.
Topics: Albuminuria; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glucosides; Kidney; Male; Malondialdehyde; NF-kappa B; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Paeonia; Phytotherapy; Rats; Rats, Wistar | 2010 |
Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.
Topics: Animals; Diabetic Nephropathies; Drug Design; Glucosides; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred Strains; Molecular Structure; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiadiazoles | 2010 |
Amelioration of STZ-induced type 1 diabetic nephropathy by aqueous extract of Enicostemma littorale Blume and swertiamarin in rats.
Topics: Administration, Oral; Animals; Biomarkers; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Drinking; Gentianaceae; Glucosides; Hypertrophy; Hypoglycemic Agents; Iridoid Glucosides; Iridoids; Kidney Glomerulus; Lipids; Male; Plant Extracts; Pyrones; Rats; Rats, Sprague-Dawley; Urea | 2010 |
Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-β1 pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biomarkers; Cell Line; Cyclooxygenase 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Glucosides; Histone Deacetylase Inhibitors; Hyperglycemia; Kidney Cortex; Male; Mesangial Cells; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirtuin 1; Stilbenes; Transforming Growth Factor beta1 | 2010 |
Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-κB signaling pathway in rat glomerular mesangial cells.
Topics: Active Transport, Cell Nucleus; Animals; Anti-Inflammatory Agents; Cell Nucleus; Cells, Cultured; Cytoprotection; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Fibronectins; Gene Expression; Glucosides; I-kappa B Proteins; Intercellular Adhesion Molecule-1; Kidney; Male; Mesangial Cells; NF-kappa B; NF-KappaB Inhibitor alpha; Organ Size; Protein Binding; Proteolysis; Rats; Rats, Sprague-Dawley; Signal Transduction; Stilbenes; Transforming Growth Factor beta | 2012 |
Total glucosides of paeony regulates JAK2/STAT3 activation and macrophage proliferation in diabetic rat kidneys.
Topics: Albuminuria; Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucosides; Janus Kinase 2; Kidney; Macrophages; Male; Paeonia; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Signal Transduction; STAT3 Transcription Factor | 2012 |
Effect of arctiin on glomerular filtration barrier damage in STZ-induced diabetic nephropathy rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Furans; Gene Expression Regulation; Glomerular Filtration Barrier; Glucosides; Glucuronidase; Intracellular Signaling Peptides and Proteins; Kidney Glomerulus; Male; Membrane Proteins; Metabolome; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin | 2013 |
Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Topics: Benzhydryl Compounds; Collagen Type IV; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Gene Expression; Glucose; Glucosides; Humans; Hypoglycemic Agents; Interleukin-6; Kidney Tubules, Proximal; NF-kappa B; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Smad3 Protein; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Toll-Like Receptor 4; Transcription Factor AP-1; Transforming Growth Factor beta1 | 2013 |
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
Topics: Animals; Blood Glucose; Carbonates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon; Glucose Tolerance Test; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Kidney Glomerulus; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Obese; Microvilli; Monosaccharide Transport Proteins; Pancreas; Phenotype; Sodium-Glucose Transporter 1 | 2001 |